LONDON and NEW YORK — February 13, 2026 — Leads & Copy — OKYO Pharma Limited (Nasdaq: OKYO) announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share.
The clinical-stage biopharmaceutical company is developing investigational therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases.
OKYO Pharma has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions.
The gross proceeds to the company from the offering are expected to be approximately $20 million, before deducting offering expenses and discounts. If the underwriter fully exercises its option to purchase additional shares, the gross proceeds could reach approximately $23 million.
The company intends to use the net proceeds from the offering primarily for clinical development of its product candidates, general corporate purposes, and working capital.
Piper Sandler & Co. is serving as the sole manager for the offering, which is expected to close on or about February 17, 2026, pending customary closing conditions.
The securities are being offered and sold under a shelf registration statement on Form F-3 (File No. 333-293145) filed with the SEC on February 2, 2026, and declared effective on February 10, 2026. The offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus that the company may file with the SEC. The final prospectus supplement will be filed with the SEC and made available on its website.
Copies of the preliminary prospectus supplement, the final prospectus supplement (when available), and the accompanying base prospectus can be obtained from Piper Sandler & Co. at 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attn: Prospectus Department, or via email at prospectus@psc.com or telephone at (800) 747-3924.
OKYO Pharma is focused on discovering and developing novel molecules for treating neuropathic corneal pain and other ocular diseases. The company recently completed a phase 2 trial of its drug urcosimod in patients with NCP and plans to initiate a Phase 2b/3 study of urcosimod to treat NCP in the first half of this year.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Statements in the release include forward looking statements regarding the closing of the Offering and the expected use of proceeds from the Offering, which are subject to risks and uncertainties.
Source: OKYO Pharma Limited
